Form 4: BioMarin Executive Awarded Equity Compensation

BioMarin Pharmaceutical's VP, Chief Accounting Officer, Rashmi Virendra Ramchandani, received grants of restricted stock units and stock options.

Summary

• Rashmi Virendra Ramchandani, VP, Chief Accounting Officer of BioMarin Pharmaceutical Inc. (BMRN), was granted equity awards.
• On January 20, 2026, 18,540 restricted stock units (RSUs) were granted, bringing the total beneficially owned RSUs to 18,540.
• An additional 7,070 restricted stock units were granted on January 20, 2026, increasing the total beneficially owned RSUs to 25,610.
• The RSUs were granted at a price of $0, as is typical for such awards.
• On January 20, 2026, 18,220 stock options were granted with an exercise price of $56.31 per share.
• These stock options begin vesting 12/48th on January 20, 2027, and 1/48th on the 20th day of each month thereafter.
• The stock options have an expiration date of January 19, 2036.

Sentiment

Score: 6

Explanation: This is a routine executive compensation event, which is generally positive for aligning management incentives with shareholder value, but does not indicate a significant change in company fundamentals.

Positives

• The equity grants align the executive's financial interests with the long-term performance and shareholder value creation of BioMarin Pharmaceutical Inc.
• Restricted stock units and stock options are common tools for executive retention and motivation.

Negatives

• The grants do not represent immediate cash value for the executive, as they are subject to vesting schedules.
• The value of the awards is dependent on the future stock performance of BioMarin Pharmaceutical Inc.

Risks

• The value of the granted equity awards is subject to market fluctuations and the overall performance of BioMarin Pharmaceutical Inc.'s stock.
• Failure to meet vesting conditions (e.g., continued employment) could result in forfeiture of unvested awards.

Future Outlook

The equity grants are designed to incentivize the executive's long-term commitment and performance, aligning their future financial success with that of the company and its shareholders.

Industry Context

Executive equity compensation, including restricted stock units and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and motivate key personnel, linking their rewards to company performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as a significant component of executive compensation is a widely adopted practice across the biotechnology and pharmaceutical industries, including companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.
• This structure is designed to incentivize long-term performance and retention, linking executive rewards directly to shareholder value creation.
• The specific vesting schedules (e.g., 4-year vesting for options) are also common, ensuring sustained commitment.

Stakeholder Impact

• Shareholders: The equity grants align the executive's incentives with long-term company performance, potentially benefiting shareholders through sustained value creation.

Next Steps

• The granted restricted stock units and stock options will vest according to their specified schedules, contingent on continued employment and other conditions.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to an executive, which is a standard part of compensation and does not provide new information to alter an investment recommendation for BioMarin Pharmaceutical Inc. The grants align executive incentives with long-term company performance.

Keywords

BioMarin Pharmaceutical, BMRN, Form 4, insider transaction, equity grant, restricted stock units, stock options, executive compensation, VP Chief Accounting Officer